Accès ouvert
2025
article
OpenAlex
Terence Diane Fabella, Joery den Hoed, Lidewij Henneman, Wendy Rodenburg et autres
Newborn screening (NBS) is evolving as novel technologies offer the opportunities to include a broader range of treatable disorders in its programs. Multiplexable, high-throughput DNA-based technologies such as next-generation sequencing (NGS) are being explored to improve and expand disease detection, although several …
nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Lindsay S. Spekreijse, Rob W.P. Simons, Björn Winkens, Frank van den Biggelaar et autres
nl, tw
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Mary van Helden, Seline A. Zwarthoff, Roel Arends, Inge Reinieren-Beeren et autres
Abstract A growing body of data from early clinical studies supports that targeting the myeloid immune checkpoint CD47-SIRPα represents a successful strategy towards establishing effective new therapies for cancer patients. Initial studies focused on CD47 blockers and more recently also SIRPα antagonistic …
nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Mary J. van Helden, Seline A. Zwarthoff, Roel J. Arends, Inge Reinieren-Beeren et autres
Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. However, CD47 is ubiquitously expressed and mediates functional interactions …
nl
(code pays fourni par la source)
2021
article
OpenAlex
Rob W.P. Simons, Laura H.P. Wielders, Rudy M.M.A. Nuijts, Claudette A. Veldhuizen et autres
PURPOSE: To investigate the cost-effectiveness of prophylactic treatments against cystoid macular edema after cataract surgery in diabetic patients. SETTING: 7 ophthalmology clinics in the Netherlands and Belgium. DESIGN: Prospective trial-based cost-effectiveness analysis using data from a European multicenter randomized clinical trial. METHODS: …
nl, us, de, gb, tw
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Hellen C.S. Römkens, Henny J. M. Beckers, Jan Schouten, Tos T. J. M. Berendschot et autres
nl
(code pays fourni par la source)
2020
article
OpenAlex
Rob W.P. Simons, Laura H.P. Wielders, Carmen D. Dirksen, Claudette A. Veldhuizen et autres
PURPOSE: To investigate the cost-effectiveness of prophylactic treatments against cystoid macular edema (CME) after cataract surgery in patients without diabetes. SETTING: Seven ophthalmology clinics in the Netherlands and Belgium. DESIGN: Prospective cost-effectiveness analysis using data from a European multicenter randomized clinical trial …
nl
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Ruud G. E. Coumans, G.J.A. Ariaans, Henri Spijker, Pascal Renart Verkerk et autres
Abstract Engineering cysteines at specific sites in antibodies to create well-defined ADCs for the treatment of cancer is a promising approach to increase the therapeutic index and helps to streamline the manufacturing process. Here, we report the development of an in silico …
us
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Frank Cornelis Theodorus van der Heide, Tan Lai Zhou, Ronald M.A. Henry, Alfons J.H.M. Houben et autres
nl
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Palwasha Mokhles, Luuk van Gorcom, Jan Schouten, Tos T. J. M. Berendschot et autres
nl
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Renske I. Wadman, Marc Jansen, Marloes Stam, Camiel A. Wijngaarde et autres
Abstract Clinical severity and treatment response vary significantly between patients with spinal muscular atrophy. The approval of therapies and the emergence of neonatal screening programmes urgently require a more detailed understanding of the genetic variants that underlie this clinical heterogeneity. We systematically …
nl
(code pays fourni par la source)
Accès ouvert
2019
article
OpenAlex
Raymon Vijzelaar, Reinier Snetselaar, Martijn J. A. M. Clausen, Amanda G. Mason et autres
Spinal Muscular Atrophy (SMA) is a disorder characterized by the degeneration of motor neurons in the spinal cord, leading to muscular atrophy. In the majority of cases, SMA is caused by the homozygous absence of the SMN1 gene. The disease severity of …
nl
(code pays fourni par la source)